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Conclusion This study suggests that patients with initial 
positive cytology may have a good prognosis following neo-
adjuvant treatment if the cytology results change to negative 
after treatment.
Keywords Gastric cancer, stomach neoplasm · 
Laparoscopy · Peritoneal cytology · Cancer staging · 
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Introduction
The main treatment of advanced nonmetastatic gastric can-
cer is surgical resection with perioperative chemotherapy 
or chemoradiotherapy [1, 2]. Efforts to prolong survival in 
metastatic gastric cancer have showed little improvement [1, 
2]. Accurate staging of gastric cancer is crucial in selecting 
the appropriate treatment option, whether curative or pallia-
tive. The Japanese Gastric Cancer Association included the 
results of cytological examination of peritoneal lavage fluid 
as a key prognostic factor in their classification of gastric 
carcinoma [1, 3]. However, recently published guidelines 
suggested that cytology-positive status in the absence of 
other noncurative factors, that is, macroscopic disease, can 
be managed with D2 gastrectomy and perioperative chemo-
therapy [4]. Initial data of those treated with surgery alone 
showed poor 5-year survival; however, more recent publica-
tions have shown that the use of postoperative chemotherapy 
improves overall survival rates to 26%, [5, 6]. On the other 
hand, if the information on cytology status were available 
before surgery, a chemotherapy-first strategy could be taken 
whereby patients whose cytology status turned negative 
could be preferentially treated with curative surgery [7, 8].
The incidence of positive peritoneal cytology for patients 
with gastric cancer varies, in published reports, from 4% to 
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Background Peritoneal cytology has been used as a part of 
the cancer staging of gastric cancer patients. The primary 
aim of this systematic review was to evaluate the value of 
peritoneal cytology as part of the staging of gastric cancer 
and survival prediction. The second aim was to establish if 
positive cytology may be modified by neoadjuvant therapy, 
to improve prognosis.
Methods An electronic literature search was performed 
using Embase, Medline, Web of Science, and Cochrane 
library databases up to January 2016. The logarithm of the 
hazard ratio (HR) with 95% confidence intervals (CI) was 
used as the primary summary statistic. Comparative studies 
were used, and the outcome measure was survival in three 
groups: (1) positive versus negative cytology at staging lapa-
roscopy immediately preceding surgery; (2) effect of neo-
adjuvant therapy on cytology and survival; and (3) positive 
cytology in the absence of macroscopic peritoneal disease 
was compared with obvious macroscopic peritoneal disease.
Results Pooled analysis demonstrated that positive 
cytology was associated with significantly reduced over-
all survival (HR, 3.46; 95% CI, 2.77–4.31; P < 0.0001). 
Interestingly, negative cytology following neoadjuvant 
chemotherapy was associated with significantly improved 
overall survival (HR, 0.42; 95% CI, 0.31–0.57; P < 0.0001). 
The absence of macroscopic peritoneal disease with positive 
cytology was associated with significantly improved overall 
survival (HR, 0.64; 95% CI, 0.56–0.73; P < 0.0001).
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41% [9]. Peritoneal washings positive for cancer cells have 
been demonstrated to correlate with the extent of cancer (T1/
T2, 0%; T3/T4, 10%; M+, 59%) [10] and have been consid-
ered as stage IV disease [11]. The influence of positive cytol-
ogy on survival has been shown as a powerful independent 
predictor of survival when compared to other postoperative 
pathological variables such as the tumor serosal invasion or 
lymph node involvement [2, 6, 12, 13]. Positive cytology 
was shown to be the most powerful predictor of outcome, 
with a risk ratio of 2.7 for patients undergoing curative 
resection [2]. Furthermore, studies have also shown that the 
number and arrangement of cytology-positive cells have an 
effect on survival at the time of gastrectomy [10, 12].
The results of the randomized controlled trial by the apan 
Clinical Oncology Group (JCOG 0705) and Korea Gastric 
Cancer Association (KGCA01), comparing gastrectomy 
plus chemotherapy versus chemotherapy alone in advanced 
gastric cancer with a single noncurable factor, showed no 
advantage of resecting the primary gastric cancer in the 
presence of peritoneal metastasis [11]. Nevertheless, the 
treatment recommendations for gastric cancer in the event 
of positive cytology range from palliative chemotherapy to 
attempts at neoadjuvant therapy followed by surgical resec-
tion [4, 14].
The aim of this study was to evaluate the value of peri-
toneal cytology as part of the staging of gastric cancer and 
survival prediction. The secondary aim is to establish if 
positive cytology may be modified by neoadjuvant therapy 
to improve prognosis.
Methods
Literature search strategy
An electronic literature search was undertaken using 
Embase, Medline, Web of Science, and Cochrane Library 
databases up to January 2016. The search terms ‘gastric can-
cer,’ ‘laparoscopy,’ ‘peritoneal cytology,’ ‘cancer staging,’ 
and ‘prognosis,’ and Medical Subject Headings (MeSH) 
‘stomach neoplasms,’ ‘neoplasm metastasis,’ ‘laparos-
copy,’ and ‘cytology’ were used in combination with the 
Boolean operators AND or OR (Fig. 1). Two authors (S.J. 
and S.R.M.) performed the electronic search independently 
in January 2016. The electronic search was supplemented 
by a hand-search of published abstracts from meetings of 
the Society of Academic and Research Surgery, Digestive 
Disease Week, the Association of Upper Gastro-Intestinal 
Surgeons of Great Britain and Ireland, and the American 
Society of Clinical Oncology for 2005–2015. The reference 
lists of articles obtained were also searched to identify fur-
ther relevant citations; as was the Current Controlled Trials 
Register (http://www.controlled-trials.com). Abstracts of the 
articles identified by the electronic search were scrutinized 
by two of the authors (S.J. and S.R.M.) to determine their 
suitability for inclusion in the pooled analysis. Any discord-
ances regarding study inclusion between these two authors 
were settled in discussion with a third independent author 
(A.A.). The quality of evidence provided by each study was 
evaluated using the Oxford levels of evidence-based medi-
cine scoring system (http://www.cebm.net/oxford-centre-
evidence-based-medicine-levels-evidence-march-2009).
Publications were included in this review if they meet the 
following criteria:
• Studies concerning patients with gastric cancer
• Comparative studies of patients with positive and nega-
tive peritoneal cytology
• Comparative studies evaluating the effect of neoadjuvant 
chemotherapy upon patients with positive cytology from 
gastric cancer
• Comparative studies of patients with positive peritoneal 
cytology in the absence of macroscopic peritoneal dis-
ease and patients with macroscopic peritoneal disease.
Publications were excluded if they met any of the follow-
ing criteria:
• Studies published in a language other than English
• Case reports or cohort studies including fewer than ten 
patients
• Noncomparative studies or studies not concerning peri-
toneal cytology and gastric cancer.
In the situation in which authors from the same institution 
had published a primary paper and then an updated analysis 
with a larger patient cohort, the most recent publication was 
included in the analysis.
Outcome measures for meta‑analysis of comparative 
studies
The primary outcome measure evaluated was the hazard 
ratio (HR) for overall survival. Three comparisons were 
made:
1. Positive versus negative cytology at staging laparoscopy 
immediately preceding surgery.
2. Initially positive cytology that became negative follow-
ing neoadjuvant therapy was compared with positive 
cytology that remained positive despite neoadjuvant 
therapy.
3. Positive cytology in the absence of macroscopic perito-
neal disease was compared with obviously macroscopic 
peritoneal disease.
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Statistical analysis
The logarithm of the hazard ratio (HR) with 95% confi-
dence intervals (CI) was used as the primary summary sta-
tistic. To estimate HR and its variance, this was extracted 
from the study directly or required additional calculation 
depending on the method of data being presented: annual 
mortality rates, survival curves, number of deaths, or per-
centage of freedom from death [15].
Meta-analysis of data was conducted using a random 
effects model. Publication bias was explored graphically 
with funnel plots to detect asymmetry and any outliers. 
Interstudy heterogeneity was assessed using the chi-square 
statistic and the I2 value to measure the degree of variation 
not attributable to chance alone: this was graded as low 
(I2 < 25%), moderate (I2 = 25–75%), or high (I2 > 75%). 
The significance level was set at P < 0.05. Calculations 
were performed by G.M. and verified by T.A. This study 
was performed in line with Cochrane recommendations, 
following the MOOSE guidelines, using appropriate sta-
tistical software (STATA/SE12) [16].
Results
Patient demographics
The total number of patients included in this meta-analysis 
was 7970, with a male to female ratio of 1:1.6 (Table 1). The 
tumor demographics have been described for each group: 
negative versus positive cytology (Table 2).
Meta‑analysis
Positive versus negative cytology
Pooled analysis of 21 studies [2, 3, 5, 9, 17–34] included 
6499 patients in total, 1052 in the positive and 4948 in the 
negative cytology group at staging laparoscopy. The median 
follow-up period ranged from 24 to 140 months. This pooled 
analysis demonstrated that positive cytology was associated 
with a significantly reduced overall survival (HR, 3.46; 95% 
CI, 2.77–4.31; P < 0.0001) (Fig. 2). There was evidence of 
significant statistical heterogeneity for this result (I2 = 84.1%).
Fig. 1  PRISMA flow diagram 
of literature search in this meta-
analysis
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Table 2  Pathological features of gastric cancer in both positive cytology (a) and negative cytology (b)
Nodal 
involvement
Primary tumor (Clinical T 
disease)
Tumor differentiation Histological type Angio-
lymphatic 
invasionT1–T2 T3–T4 Differentiated Poorly dif-
ferentiated
Intestinal Diffuse
(a) Positive cytology
 Badgwel 6 30
 Bentrem 150 4 19
 Brito 5 0–2(5), 3–4 (37) 5 3 5
 Chuwa 28 0 36
 Euanoraster 22 14 2 20 18
 Fukagawa 234 307
 Jiang 29 3 35 14 24 18 20 17
 Kang 5 0 7 1 6
 Katsuragi 34 5 41 14 11
 Kodera 20 2 20
 La Torre 7 1 6
 Lee 105 6 102 31 141 37 55
 Makino 28 35 5 30
 de Manzoni 13 0 23 9 14
 Miyashiro 25 10 15 7 18
 Nakagawa
 Noda 88 2 89 33 58 41
 Riheiro 14 0 15 6 9
 Rosenberg 57 36 38
 Wong 2 0 2 1 1 1 1 4
(b) Negative cytology
 Badgwel 45 165
 Bentrem 14 172 48
 Brito 42 5 3 36 26
 Chuwa 44 46 60 24
 Euanoraster 61 14 61 25 50
 Fukagawa 6 13 21
 Jiang 53 40 61 41 60 46 55
 Kang 46 23 45 25 43 14
 Katsuragi 46 47 23 33 37
 Kodera 29 6 31
 La Torre 36 39 18
 Lee 648 368 429 271 629 359 367
 Makino 49 78 35 43
 de Manzoni 77 78 67 83 62
 Miyashiro
 Nakagawa 559
 Noda 977 411 972 577 806
 Ribeiro 131 66 120 85 101
 Rosenberg 114 223 49
 Wong
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Following neoadjuvant therapy: positive versus negative 
cytology
Pooled analysis of five studies [7, 24, 35–37] included 519 
patients in total; 73 in the positive cytology and 139 in the 
negative cytology group. The median follow-up period 
ranged from 60 to 84 months. This pooled analysis demon-
strated that negative cytology following neoadjuvant chemo-
therapy was associated with significantly improved overall 
survival (HR, 0.42; 95% CI, 0.31–0.57; P < 0.0001) (Fig. 3). 
There was evidence of significant statistical heterogeneity 
for this result (I2 = 62.5%).
Positive cytology versus macroscopic peritoneal disease
Pooled analysis of seven studies [3, 7, 9, 17, 20, 25] 
included 1035 patients in total, 465 in the positive cytology 
and 537 in the macroscopic peritoneal disease group. The 
median follow-up period ranged from 36 to 120 months. 
This pooled analysis demonstrated that positive cytology 
in the absence of macroscopic peritoneal disease was asso-
ciated with a significantly improved overall survival (HR, 
0.64; 95% CI, 0.56–0.73; P < 0.0001) (Fig. 4). There was 
no evidence of significant statistical heterogeneity for this 
result (I2 = 0%).
Bias exploration/sensitivity analyses
Funnel plots were created for combined and subgroup analy-
sis for the various factors to visually assess the publication 
bias; these demonstrated symmetry. To determine the influ-
ence of each study’s individual dataset, we performed sensi-
tivity analyses for the subgroups as described. A single study 
involved in the pooled meta-analysis was excluded each 
time, and the corresponding HR was not changed notice-
ably (data not shown).
Discussion
This meta-analysis has demonstrated negative peritoneal 
cytology before treatment improves survival rate when com-
pared with positive cytology. Cytology should be considered 
a modifiable factor as it was found in this meta-analysis, 
that the change in cytology status from a positive to nega-
tive result following chemotherapy was shown to carry an 
improvement in overall survival. Furthermore, although pos-
itive cytology is considered stage IV disease, the prognosis 
and overall survival associated with positive cytology versus 
macroscopic peritoneal metastasis are not equivalent [31]. 
Fujiwara et al. have shown that the change in cytology status 
to negative following receiving neo-adjuvant intraperitoneal 
Fig. 2  Forrest plot of pooled 
analysis demonstrated that posi-
tive cytology results were asso-
ciated with significantly reduced 
overall survival (HR, 3.46; 95% 
CI, 2.77–4.31; P < 0.0001)
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chemotherapy and systemic chemotherapy improved progno-
sis [37]. It is worth noting that although Lorenzen et al. have 
also shown that the change in cytological status to negative 
following chemotherapy led to improved prognosis, almost 
25% with negative cytology became positive following 
chemotherapy, thus worsening their prognosis and outcome 
[36]. The prediction of response of patients to neoadjuvant 
therapy as assessed by cytology remains a challenging area 
for future research to provide patient- and tumor-targeted 
therapy.
Regarding peritoneal disease, this meta-analysis has 
shown that positive cytology alone carries better sur-
vival compared with macroscopic peritoneal dissemina-
tion. Although survival with no treatment can be similar 
between these two groups, the use of neo-adjuvant chemo-
therapy was shown to improve the 3-year overall survival 
from 0% in gross peritoneal disease to 12% in positive 
cytology with no overt peritoneal disease [9]. Therefore, 
the concept that positive cytology is a potentially modifi-
able factor is further supported. Interestingly, Miyashiro 
Fig. 3  Forrest plot for pooled 
analysis demonstrated that nega-
tive cytology results following 
neoadjuvant chemotherapy were 
associated with significantly 
improved overall survival 
(HR, 0.42; 95% CI, 0.31–0.57; 
P < 0.0001)
Fig. 4  Pooled analysis demon-
strated that positive cytology 
in the absence of macroscopic 
peritoneal disease was associ-
ated with significantly improved 
overall survival (HR, 0.64; 95% 
CI, 0.56–0.73; P < 0.0001)
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et al. also studied the number of cancer cells detected in 
cytology studies versus peritoneal metastasis and found 
that when a higher number of cells was detected, survival 
was similar to those with peritoneal metastasis [3]. There 
was insufficient evidence available to define a threshold 
of positive cancer cells from cytology that changed sur-
vival from this review, which remains an important area 
for future research.
There are a number of limitations to this systematic 
review and meta-analysis that need to be acknowledged. 
First, the lack of randomized control trials (RCTs) that met 
the inclusion criteria is therefore reducing the power of the 
analyses. Second, only studies in the English-language lit-
erature were included, so it is possible that relevant stud-
ies in other languages will be identified in the future. Also, 
patient demographics and co-morbidities were not reported 
in all the included studies.
In conclusion, the results of this meta-analysis support 
the importance of peritoneal cytology results in the assess-
ment of gastric cancer patients. We have shown that nega-
tive cytology and the change in cytological status from 
positive to negative improve survival in gastric cancer. This 
knowledge justifies the notion to reconsider the presence of 
positive peritoneal cytology as an absolute indication for 
palliative intent of treatment without further consideration 
to changing status following chemotherapy (Fig. 5). The 
change of initial positive cytology to negative subsequent to 
treatment should be the subject of a prospective large-scale 
multicenter study that examines long-term survival benefits.
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